Perrigo's stock price fell by 25.35% over the last 12 months but experienced a strong rally in the past six months, gaining 44% and trading near the upper end of its 52-week range by early November 2026. In Q1 2026, Perrigo reported an 8.3% year-over-year decline in core net sales due to softer consumption, particularly in cough and cold categories, and retailer inventory destocking, though the company maintained its full-year guidance. Q2 2026 saw sequential improvement in its Core business. Perrigo attended the Barclays Global Consumer Conference on August 27, 2026. On October 29, 2026, Perrigo announced an agreement to sell its Infant Formula business for up to $175 million, a move expected to simplify its portfolio, enhance its margin profile, reduce future capital expenditures, and support debt reduction, while anticipating an impairment loss between $275 million and $375 million in Q4 2026. Concurrently, a quarterly dividend of $0.29 per share was announced. Q3 2026 financial results, reported on November 4, 2026, showed a 1.7% year-over-year decline in core net sales, indicating sequential improvement from prior quarters, but sales were still impacted by softer European demand, cautious retailer inventory positioning, and lower contract manufacturing volumes. Adjusted EPS of $0.60 beat analyst expectations, while revenue of $989 million missed the consensus, leading the company to update its full-year 2026 outlook to reflect the infant formula divestiture and continued softness in Europe.